According to Ascendis Pharma
's latest financial reports the company has $0.34 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $0.44 B | -43.93% |
2022-12-31 | $0.78 B | 1.97% |
2021-12-31 | $0.77 B | -12.63% |
2020-12-31 | $0.88 B | 31.95% |
2019-12-31 | $0.67 B | 110.78% |
2018-12-31 | $0.31 B | 35.54% |
2017-12-31 | $0.23 B | 23.54% |
2016-12-31 | $0.18 B | 45.1% |
2015-12-31 | $0.13 B | 114.42% |
2014-12-31 | $61.01 M | 127.38% |
2013-12-31 | $26.83 M | 39.56% |
2012-12-31 | $19.22 M | -5.41% |
2011-12-31 | $20.32 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Akebia Therapeutics AKBA | $42.92 M | -87.58% | ๐บ๐ธ USA |
Affimed
AFMD | $80.59 M | -76.68% | ๐ฉ๐ช Germany |
Advaxis ADXS | $4.88 M | -98.59% | ๐บ๐ธ USA |